Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Giovanni.. so the FDA is grossly understaffed. Then why in the world is the administration sending 55 Billion dollars to Africa in aid over the next 3 years. A large chunk of that should first go to the FDA to help them get life saving drugs out to human beings.
Giov.. I've posted many times that I feel that FDA needs congressional oversight. Without that there will be corruption with officials 'on the take'. And those PDUFA fees are very lucrative, and they waive a carrot in front of FDA decision makers. There is too much of a cloud of secrecy with the FDA. More transparence is needed.
They will have money if they strike an investment deal. I don't feel that their products are attractive enough (from an ROI perspective) to persuade Big Pharm to invest in them. They have nothing that is FDA approved, so Big Pharm would need to see monster ROI before they would finance that operation. JMHO.
Yes, but nice for swing trading.
I would also be concerned that any buyout would also entail a massive (undesirable) R/S in order to make the financial statements more attractive. No, I'm willing to be patient.
It does sound like Arthur is in negotiations with a possible investor(s), so they don't want to jeopardize those negotiations. I think it makes sense to let the negotiations with the multiple options they are seeking .....work their course. Patience is sometimes a virtual.
Well, thus far revive has been exhibiting the same downward trajectory as relief. The only thing revive has going for is its lower float, but that may not last long because they need to pay the their high salaries and bonuses.
That's not how the FDA works.
relief is not over. They'll be on the NASDAQ by spring per the ADR process.
No, I stopped swing trading this after the price collapsed. Silence is the killer with tiny biotechs looking to capitalize on covid.
What PR lie?
So you are not aware of material event that specifically hurt KNDI?
Over the years I've successfully swing traded KNDI quite a bit. But over the 12 months I haven't been working it. I'm thinking about working it again though. They appear to have some momentum on sales growth.
mick.... so what is your read as to why KNDI has been in a nose dive over the past 30 days? Thanks
ACER is on another run again (up 45%). If the the Jan 15 PDUFA is a success, that means some nice future revenues for both ACER and RLFTF !
ACER is on another run again (up 45%). If the the Jan 15 PDUFA is a success, that means some nice future revenues for RLFTF !
panton...nice profit deal recap!
Bernardino gives ACER shares a Buy rating, and his $12 price target implies a hefty upside of 664% for the coming year. (To watch Bernardino’s track record, click here)
Turning now to the rest of the Street, other analysts are on the same page. With 3 Buys and no Holds or Sells, the word on the Street is that ACER is a Strong Buy. The stock has a $9.67 average price target and a share price of $1.57, for a one-year upside potential of ~516%
ACER is on a 'run'. Remember.
PDUFA date is January 15, 2023.
Good PR out on this.
https://finance.yahoo.com/news/2-biotech-stocks-under-10-023527396.html
ACER is on a 'run'. Remember....RLFTF receives a chunk of the profits from the sale of ACER-001.
PDUFA date is January 15, 2023.
Good PR out on this.
https://finance.yahoo.com/news/2-biotech-stocks-under-10-023527396.html
What prevents someone from putting a thin film of vaseline (or some clear, non-porous lotion) on one's finger before applying it to the detector? I asked the company via email 3 weeks ago and they never responded. Has this question been raised here before?
Joe, it's my understanding that the R/S only impacts you if you own ADRs. I never bought any, nor have I converted my RLFTF OTC shares to ADRs. I'm still waiting for RLFTF to 'force' me to convert my OTC shares to ADRs.
What's not clear to me is what impact will the ADR R/S have on the price of RLFTF. I suspect none. But I could be wrong. This whole ADR initiative is weird stuff that RAM is doing, and he doesn't communicate the mechanics of his intent to the SH. Other than his goal is to eventually convert all RLFTF shares to ADRs. I'm holding my breath on that one.
Hopefully someone else here who is 'in the know' on the ADRs can post on this topic.
Volume Profile is pretty good for that. Requires a bit of training to use though.
Very Interesting!
What about the warnings regarding taking too much zinc dosage? I think I read to take it just once a week (not daily).
The paperwork that came with my Paxlovid provided a longggg list of ailments that would qualify someone for the drug.
You mention Zinc and D-3. What about Vit C?
Naught. prior to catching covid, I did have four jabs though (the latter two being the booster shots). I don't know for certain, but those jabs may very well have contributed to how quickly I recovered after taking those little pills.
Naught, yes, I was told to take 2 pills a day for 5 days ...starting immediately. I had no side effects. It worked great for me.
The doctor also asked me - 'when' did I start having covid symptoms. I told him they started the day before. So he was making sure that I wasn't on day 3, 4, 5.... You may want to check with your doctor on what rules he/she is following on that pill. I think if you are under 50 (or 60) they won't give it to you because it is operating under EUA (not fully tested long term). Unless you are at risk (dabetes, etc.) It's always good to have a plan of attack before you catch covid.
mypennys..btw, apparently the way that little pill (paxlovid) works is it stops the virus from replicating itself. It doesn't kill the covid virus, it just halts its duplication thus giving the body's immune system a chance to go after it. That's why if you wait too long (more than 3 days after symptoms) then it is usually too late for it to help that much. That's my understanding. It doesn't kill the virus, it just prevents it from reproducing itself.
My PCP prescribed them as SOC. The FDA granted it EUA under the COVID umbrella. But I believe you have to be over 50 or 60 to get them, OR have any type of illness that puts you at more risk (ex: diabetes). Your doctor just have to sign off on it. Two pills a day for five days. It knocked out COVID in 2 days for me.
Mountain...thanks for the update! Much appreciated.
Yes, I knew they had issues with marketing when they paid that no-name skateboard fellow to advertise.
Up 800% today. If we could do that every day, we'd be in great shape in a couple of weeks.
That would be HUGE for the trial, because today's SOC is pretty darn good compared to two years ago. Last month I caught COVID for the first time (I'm in my 60s) and I was pretty damn sick on day 1!! But I immediately started popping those paxlovid pills and by day 3 COVID was completely behind me. So the SOC for me last month with that pill was very, very good. But one has to get on that pill asap and not wait several days for the virus to take a deep hold. Having said that, I could have been one of the positive outliers with that SOC.
On the other hand ----- if a PR is released that broadcasts that SOBR just clinched a new, sizable revenue generating deal/contract.... we'll could see this pop to $3+, and then the prior technical charts and indicators can be pitched into the recycle bin.... and start over.
Yes, it makes perfect sense to change the endpoint. This risk is it's a moving target. In the case of rlftf they discovered that due to the evolving/improving SOC (standard of care) in hospitals, that it became harder to compete with SOC over time. So the FDA agreed to let them move their endpoint out from 30 days to 60 days. Which was still not enough to compete with the ever-improving SOC. Two+ years ago, before SOC evolved, the EUA would have been a slam dunk for Relief (and possibly for Revive too).
The key (that many folks miss) is these drugs are being compared to SOC in the Control Group. As SOC evolves and improves, relatively speaking the benefits of the drug diminishes over time. Relief even has before and after xrays (anecdotal evidence) demonstrating clear and obvious COVID improvement....however that was 2+ years ago before SOC evolved. As they say.... slow you blow, snooze you lose (unfortunately). So the million dollar question here is... how will Bucillamine compare to today's version of SOC. JMHO
That would be sweet!
Rick.... RVVTF is following the same FDA EUA path by redefining their primary endpoints with hopes that the new endpoints will help them with gaining EUA. The jury is out on whether that will be successful or not. That little trick did not work for Relief though.
The similarity between the two drugs is they are both trying to slip under the COVID therapeutic wire, and they are both tiny, foreign entity penny stocks. Unfortunately the FDA is tends to favor USA based pharmaceuticals, and/or Big Pharm in general. So RVVTF does have a shot at it. I'm just not optimistic based on the FDA track record. Nor am I bearish though.
What you are omitting is the Relief drug (aviptadil) was essentially stolen and received full EUA in India. It's being used there with patients now. Also, the NIH / FDA trial was with the IV version of the drug, not inhaled. You are missing a ton of DD. Not that it matters.
Yep....forward progress is dependent on: 1) revenues OR 2) securing financing
Because changing endpoints is not always a panacea. The FDA agreed to let RLFTF change their primary endpoint. Everybody was happy about that !!! But then after all of that fuss and excitement, they failed to meet the new, shiny primary endpoint. It's a Hail Mary. Yes, sometimes it can work. Maybe it will here with RVVTF. I'm not bearish or bullish here, because it's like a crapshoot. I can't predict the FDA's behavior either.